New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies (Volume II)

Dear Colleagues,

We are excited to invite you to contribute to this Special Issue, which is the second edition of "New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies" (https://www.mdpi.com/journal/cancers/special_issues/haematological_malignancies).

It is our pleasure to announce a call for submissions to this Special Issue of Cancers, titled "New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies".

Blood cancer is one is the major causes of cancer death worldwide. Patients have increased chances of surviving if the disease is diagnosed earlier, and people have access to better personalised therapies. Additionally, toxicities and long-term adverse effects, including organ damage, are often associated with current blood cancer therapies and impair life quality. In the last decade, novel genetic, epigenetic, metabolic, and immunological vulnerabilities have been identified and, in some cases, have led to the development of new targeted therapies. However, despite rapid initial responses, disease often recurs with an often-fatal outcome. We welcome original research articles and reviews that cover any relevant topics in this area. Possible topics include, but are not limited to, the following:

• Role of the immune system in blood cancer progression and relapse and advances in immunotherapies.
• Mechanisms of resistance and targeted therapies.
• Genomic and epigenetic mechanisms influencing clinical outcome, including mutations, gene fusions, copy number variations, and other chromosomal rearrangements.
• Exploiting metabolic vulnerabilities for personalised therapies, including mutations in key metabolic enzymes.
• Side effects and toxicities of the current blood cancer therapies and strategies for reducing them.
• Omics approaches, including single-cell technologies, for identifying new biomarkers.
• RAS pathway mutations in blood cancer and new targeted therapies.
• The tumour microenvironment, cell dormancy, and relapse.

We look forward to receiving your contributions.

Dr. Ilaria Stefania Pagani
Dr. Teresa Sadras
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• blood cancer
• cancer relapse
• resistance
• targeted therapies
• immune therapies
• metabolism
• cancer mutations